MedPath

The Role of Milk Derived Peptides on Glycaemic Control

Not Applicable
Completed
Conditions
Insulin Resistance
Interventions
Dietary Supplement: Parent Protein
Dietary Supplement: Water Control
Dietary Supplement: Milk derived hydrolysate
Other: Lipid Load
Registration Number
NCT03102463
Lead Sponsor
University College Dublin
Brief Summary

This study aims to ascertain the potential of novel milk derived hydrolysates to improve glycaemic control to promote metabolic health. A comprehensive characterisation of the metabolic response to these milk derived hydrolysates will ascertain the effect of the hydrolysates in terms of insulin sensitivity. These hydrolysates have been shown to improve insulin resistance in cell and animal models. Therefore the investigators aim is to test their efficacy in overweight, insulin resistant individuals at risk of developing type 2 diabetes.

Detailed Description

Recent figures estimate 60% of Irish adults are overweight or obese. As obesity is associated with the development of insulin resistance, which precedes type 2 diabetes development by decades, novel food based solutions are required to improve glycaemic control and attenuate insulin resistance.

In the current study insulin resistant individuals will undergo 4 study visits, 1 screening visit and 3 subsequent visits. At each of the 3 visits they will receive an oral lipid load consisting of 100mL soya bean oil, followed by either a water control; the hydrolysate being tested or the parent protein from which the hydrolysate was derived. After which they will undergo a 4 hour hyperinsulinemic-euglycaemic clamp at each visit to assess their insulin sensitivity.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Age 18 - 65 years
  • BMI > 26 kg/m2
  • Prepared to maintain a constant body weight for the duration of the study
  • Free of any chronic or infectious disease
  • Not taking any medication for the regulation of blood sugars
  • Diet controlled type 2 diabetes
  • Free of any milk allergies or lactose intolerance
  • Without anaemia
Exclusion Criteria
  • <18 or >65 years
  • Diabetes (pharmacologically treated) or other endocrine disorders.
  • Chronic inflammatory conditions.
  • Kidney or liver dysfunction.
  • Anaemia (Haemoglobin <12g/dl men, < 11g/dl women).
  • Taking any medication for the regulation of blood sugars.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Parent ProteinParent Protein-
Water ControlWater Control-
Milk derived hydrolysateMilk derived hydrolysate-
Milk derived hydrolysateLipid Load-
Water ControlLipid Load-
Parent ProteinLipid Load-
Primary Outcome Measures
NameTimeMethod
Glucose Disposal Rate12 weeks

M-value (mg/kg/min) /Glucose disposal rate will be used to measure of insulin sensitivity

Secondary Outcome Measures
NameTimeMethod
Markers of glycaemic control12 weeks

Insulin (mU/L)inflammatory markers

Inflammatory Markers12 weeks

C-peptide (ng/mL) and other related

Lipid Profile12 weeks

Triglycerides (mmol/L) and other related lipid markers

Trial Locations

Locations (1)

St Vincent's University Hospital

🇮🇪

Dublin, Ireland

© Copyright 2025. All Rights Reserved by MedPath